Drugs / anti-GPC3 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04951141 | Jan 2019 → Sep 2023 | cholangiocarcinoma, hepatocellular carcinoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-GPC3 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04951141 ↗ |
| Modality | Cell therapy | “anti-GPC3 CAR-T cells” NCT04951141 ↗ |
| Route | Other | “intratumoral injection” NCT04951141 ↗ |
| Target | GPC3 | “anti-GPC3 CAR-T cells” NCT04951141 ↗ |